• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Evidence & Protoc

  2026-07-02

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) enables robust, low-immunogenicity bioluminescent reporter assays. Its Cap1 and 5-moU modifications enhance mRNA stability, translation, and immune evasion, facilitating sensitive applications in gene regulation and cell viability studies.

• Patient-Derived 3D Spheroids: Advanced Prostate Cancer Model

  2026-07-02

  This study introduces patient-derived 3D spheroid cultures from radical prostatectomy specimens as a translational model for organ-confined prostate cancer. By enabling extended culture viability and drug response testing, the model advances preclinical research and supports more physiologically relevant investigations of tumor biology and therapeutic efficacy.

• VX-745: Expanding Horizons in p38α MAPK Inhibitor Research

  2026-07-01

  Explore how VX-745, a potent p38α MAPK inhibitor, pioneers new assay strategies through dual-action kinase modulation. This article delivers a deep-dive into mechanistic insights, protocol optimization, and the impact of recent structural biology breakthroughs.

• Dual-Action Modulation of p38α MAPK: Inhibitor-Induced Depho

  2026-07-01

  The recent study by Stadnicki et al. elucidates how certain kinase inhibitors, including those targeting p38α MAP kinase, can simultaneously block kinase activity and accelerate dephosphorylation of the activation loop by phosphatase WIP1. This dual-action mechanism advances the conceptual framework for kinase inhibitor design and may open new avenues for increasing drug specificity in inflammatory disease research.

• QSHXO Mitigates MASLD via Autophagy Activation and Ferroptos

  2026-06-30

  This study elucidates how Qushi Huoxue ointment (QSHXO) ameliorates metabolic associated steatotic liver disease (MASLD) by concurrently activating autophagy and inhibiting ferroptosis in a murine model. The findings clarify mechanistic links between cell stress pathways and MASLD pathology, providing a foundation for future interventions targeting autophagy and the Nrf2 axis.

• Reserpine (N1867): Technical Guidance for Lab Research Workf

  2026-06-30

  Reserpine (SKU N1867) addresses reproducibility challenges in neurotransmitter depletion and antihypertensive mechanism research by providing a high-purity, well-characterized standard. It is not suitable for diagnostics or therapeutic use and requires strict adherence to solubility and storage protocols to maintain experimental integrity.

• Phenothiazines Enhance Macrophage Antibacterial Activity via

  2026-06-29

  The referenced study demonstrates that phenothiazine compounds, including promethazine hydrochloride, significantly augment the antibacterial activity of macrophages by inducing reactive oxygen species (ROS) and autophagy. This host-directed mechanism offers a promising alternative to traditional antibiotics, particularly in addressing intracellular pathogens and rising antimicrobial resistance.

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: Precision Cont

  2026-06-29

  Using 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP 3) as a negative control unlocks unparalleled specificity in Src kinase pathway research, enabling rigorous validation of inhibitor selectivity and off-target effects. This guide translates cutting-edge findings into actionable workflows and troubleshooting tips for maximizing reproducibility in vascular and cellular signaling studies.

• EVMPs Enable Extrahepatic Targeting for mRNA Delivery

  2026-06-28

  This study presents a bottom-up approach to engineering enveloped virus-mimicking particles (EVMPs) for efficient, safe, and organ-selective delivery of mRNA beyond the liver. The findings represent a significant advance in overcoming the hepatic tropism of current mRNA delivery systems, with strong implications for extrahepatic gene therapies.

• Phenothiazines Enhance Macrophage Antibacterial Defense via

  2026-06-27

  The referenced study uncovers how phenothiazines, including promethazine hydrochloride, enhance the antibacterial activity of macrophages by inducing both reactive oxygen species (ROS) and autophagy. These findings provide a mechanistic foundation for host-directed therapies targeting intracellular pathogens and offer new directions for inflammation and immunology research.

• Dacomitinib (PF-00299804): Pan-HER Inhibition in Cancer Rese

  2026-06-26

  Dacomitinib (PF-00299804) is a potent, irreversible pan-HER inhibitor used in cancer research. It targets EGFR, HER2, and HER4 kinases, induces apoptosis and cell cycle G0–G1 arrest, and demonstrates efficacy in models resistant to standard therapies. This article details its molecular action, protocol integration, and current research boundaries.

• FASN Inhibition Primes Mitochondrial Apoptosis in Cancer Cel

  2026-06-26

  This study uncovers how fatty acid synthase (FASN) inhibition increases mitochondrial apoptotic priming in cancer cells, sensitizing them to BCL-2 family inhibitors such as ABT-263 (Navitoclax). The findings provide mechanistic insight into FASN’s role in regulating apoptotic thresholds and suggest that combining FASN inhibitors with BH3 mimetics could enhance antitumor efficacy.

• Linoleic Acid (C18:2(9Z,12Z)): Technical Guidance for Lab Us

  2026-06-25

  Linoleic Acid (C18:2(9Z,12Z), SKU C3108) addresses research needs in membrane fluidity, oxidative stress modeling, and essential fatty acid deficiency, especially in cell-based and animal workflows. It should not be used in protocols demanding aqueous solubility or long-term stock solutions; its application is best when freshly prepared and handled under validated lab protocols.

• Promethazine HCl in Research: Protocols and Innovations

  2026-06-25

  Promethazine HCl is redefining inflammation and neuroscience workflows by enabling precise modulation of histaminergic and host defense pathways. This guide details advanced experimental applications, troubleshooting strategies, and new insights from recent macrophage research, empowering labs to harness promethazine hydrochloride for superior reproducibility and data quality.

• Humanized Gs-DREADD Enables Precise Neural Circuit Modulatio

  2026-06-24

  This study introduces a fully humanized Gs-coupled DREADD, hM3Ds, addressing immunogenicity concerns of earlier non-human chemogenetic tools. The research demonstrates hM3Ds' comparable efficacy to rodent rM3Ds in activating specific neural pathways and alleviating Parkinsonian symptoms in a mouse model, supporting its translational potential for both basic and clinical neuroscience.

16310 records 1/1088 page Next 12345 下5页 Last page